Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy
Gut and Liver
;
: 298-305, 2017.
Article
in English
| WPRIM
| ID: wpr-69988
ABSTRACT
BACKGROUND/AIMS:
Second-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma (PDAC) that progresses following gemcitabine-based treatment has not been established. This study aimed to investigate the efficacy and safety of second-line combination chemotherapy with capecitabine and oxaliplatin (XELOX) in these patients.METHODS:
Between August 2011 and May 2014, all patients who received at least one cycle of XELOX (capecitabine, 1,000 mg/m² twice daily for 14 days; oxaliplatin, 130 mg/m² on day 1 of a 3-week cycle) combination chemotherapy for unresectable or recurrent PDAC were retrospectively recruited. The response was evaluated every 9 weeks, and the tumor response rate, progression-free survival and overall survival, and adverse events were assessed.RESULTS:
Sixty-two patients were included; seven patients (11.3%) had a partial tumor response, and 20 patients (32.3%) had stable disease. The median progression-free and overall survival were 88 days (range, 35.1 to 140.9 days) and 158 days (range, 118.1 to 197.9 days), respectively. Patients who remained stable longer with frontline therapy (≥120 days) exhibited significantly longer progression-free and overall survival. The most common grade 3 to 4 adverse events in patients were vomiting (8.1%) and anorexia (6.5%). There was one treatment-related mortality caused by severe neutropenia and typhlitis.CONCLUSIONS:
Second-line XELOX combination chemotherapy demonstrated an acceptable response and survival rate in patients with advanced PDAC who had failed gemcitabine-based chemotherapy.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pancreatic Ducts
/
Pancreatic Neoplasms
/
Vomiting
/
Adenocarcinoma
/
Anorexia
/
Survival Rate
/
Retrospective Studies
/
Mortality
/
Treatment Outcome
/
Salvage Therapy
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Gut and Liver
Year:
2017
Type:
Article
Similar
MEDLINE
...
LILACS
LIS